Pharsight Cuts Additional 20 Percent of Staff as Restructuring Heats Up | GenomeWeb

NEW YORK, Nov. 21 - Two weeks after being delisted from the Nasdaq exchange, Pharsight said it will dismiss 20 percent of its staff and cut second-tier products and services.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.